Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genticel Secures EUR 18.2 Million (USD 23.7 million) in Capital Funding

Published: Friday, April 26, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
Dr. Rainer Strohmenger joins the supervisory board of Genticel.

Genticel has announced that it has raised EUR 18.2 million (USD 23.7 million) in additional capital. Wellington Partners, based in Munich, Germany, led the round which included all current institutional investors i.e. IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund, IRDI and Amundi Private Equity Funds.

Dr. Rainer Strohmenger, general partner at Wellington Partners, joins the supervisory board of Genticel.

Genticel is a France-based vaccine developer that focuses on therapeutic vaccines against high risk human papillomavirus (HPV) infection.

The company has been spearheading the development of vaccine solutions for women infected with high-risk HPV types (16 and 18) but who have not yet progressed to cervical high grade lesions or cancer.

Today, no therapeutic options are available for this very large population of women whose medical need has only recently been revealed by the increasing availability of HPV screening.

These tests are rapidly being adopted in first line cervical cancer screening programs in the USA and Europe.

The first preventive vaccines against high risk HPV 16/18 infections were introduced into global markets as of 2006 and have seen widespread adoption.

However, there is still no effective treatment against established infection with high-risk HPV types.

ProCervix, Genticel’s lead product is a unique proprietary HPV16/18 vaccine for the treatment of infected women who have not yet developed high-grade cervical lesions or cancer. ProCervix is designed to eliminate HPV16 and/or 18 infected cells.

The new funds will be used to advance Genticel’s key product candidates, i.e., two therapeutic HPV vaccines. The lead vaccine, ProCervix, has successfully finished phase I clinical study.

The phase I trial (n=47) revealed no dose limiting toxicity and no patient drop-out. In addition, ProCervix induced a dose-dependent immune response as well as viral clearance in a substantially larger percentage of patients as compared to placebo.

ProCervix will enter into phase II development in order to demonstrate proof of efficacy. This bivalent product, built on Genticel’s proprietary CyaA antigen delivery technology, carries antigens originating from both HPV16 and HPV18.

Genticel’s other pipeline product is a CyaA-based multivalent HPV vaccine with additional virus subtype coverage.

“The commitment from Wellington Partners, one of the most reputable life science investors in Europe, is further endorsement of Genticel’s therapeutic HPV vaccine development,” said Benedikt Timmerman, founder and CEO of Genticel.

Timmerman continued, “The Wellington life science team members are bringing outstanding clinical development and medical expertise to our shareholder base, both from therapeutic vaccines and from cervical cancer screening. They have immediately understood the unique properties of our lead product ProCervix. This investment will allow us to take ProCervix through a multi-center multi-national phase II program. It will further strengthen our database supporting the efficacy and safety of this highly novel, curative treatment for high-risk HPV-infections.”

“We are highly excited about Genticel’s lead project ProCervix,” added Dr. Rainer Strohmenger, general partner at Wellington Partners. “It showed compelling data in the phase I clinical trial suggesting that it can cure an infection with high-risk HPV types 16 and 18 in 3 out of 4 treated patients, thus effectively preventing progression of the infection to high-grade cervical disease. There are more than 90 million women in the world infected with HPV 16 and/or HPV18 types who could benefit from this treatment, making this market a clear blockbuster opportunity.”

Recent estimates by the World Health Organization suggest that world-wide approximately 300 million women are carriers of HPV infection at any given time and approximately 500,000 patients are diagnosed with cervical cancer each year.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genticel Launches its Phase II Trial in Women Infected with High-Risk HPV
The appointment of Dr. Sophie Olivier as chief medical officer completes the Genticel team to run the Phase II trial across Europe.
Thursday, March 06, 2014
Scientific News
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!